BridgeBio Pharma BBIO Total debt
Total debt at other companies
Other financials
Where this comes from
Calculated from BridgeBio Pharma’s reported figures.
Plus components not separately reported this period.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's total debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's total debt?
- BridgeBio Pharma (BBIO) reported total debt of $3.26B in Q1 2026.
- How has BridgeBio Pharma's total debt changed year-over-year?
- BridgeBio Pharma's total debt increased by 32101.0% year-over-year, from $10.12M to $3.26B.
- What is the long-term trend for BridgeBio Pharma's total debt?
- Over 5 years (2020 to 2025), BridgeBio Pharma's total debt has grown at a -38.5% compound annual growth rate (CAGR), from $114.05M to $10M.
- What does total debt mean?
- The total amount of money a company owes to lenders and creditors through loans, bonds, and other debt instruments.
- How do you interpret total debt?
- An increase in total debt suggests higher financial leverage and increased interest expense, which may heighten liquidity risk for pre-revenue or early-stage companies. Conversely, a decrease indicates deleveraging, which can improve the balance sheet's health but may also signal limited access to capital markets or a strategic shift in funding.
- How does total debt compare across companies?
- In the biotechnology sector, total debt levels vary significantly based on the company's stage of development; early-stage firms often maintain lower debt to avoid interest burdens, while mature firms may utilize debt to finance late-stage clinical trials or commercialization efforts.